TriSalus Life Sciences Names Richard Marshall, MD, Chief Medical Officer
TriSalus Life Sciences, a clinical-stage oncology company focused on integrating innovative drug delivery technologies with standard-of-care therapies and immunotherapeutic approaches, has announced the appointment of Richard Marshall, MD, as its Chief Medical Officer (CMO), effective June 29, 2026. This appointment marks a significant step in the company’s efforts to strengthen its executive leadership team as it advances its clinical and strategic initiatives aimed at transforming treatment outcomes for patients with solid tumors.
Dr. Marshall will assume the CMO role on a full-time basis, transitioning from his current position as Medical Director, a role he has held since January 2025. In his expanded capacity, he will be responsible for leading the company’s overall medical strategy, guiding clinical development programs, overseeing evidence generation, and supporting broader corporate and scientific initiatives. His appointment comes at a time when TriSalus is actively progressing its proprietary technologies and building clinical evidence to support their use across multiple oncology indications.
TriSalus Life Sciences is focused on addressing the limitations of traditional cancer therapies by combining advanced delivery technologies with innovative therapeutic approaches. Central to its platform is the Pressure-Enabled Drug Delivery (PEDD) system, which is designed to improve the distribution and penetration of therapeutics directly into tumors. This approach aims to enhance treatment efficacy while minimizing systemic toxicity, a key challenge in oncology care. The company is also advancing its TriNav product suite, which supports the delivery of therapies using this specialized technology.
Commenting on the leadership transition, Mary Szela, President and Chief Executive Officer of TriSalus, highlighted Dr. Marshall’s unique qualifications and contributions to the organization. She emphasized that his combination of frontline clinical experience and deep expertise in interventional oncology aligns closely with the company’s mission to improve outcomes for patients with complex cancers. Since joining TriSalus as Medical Director, Dr. Marshall has played a critical role in expanding the application of the company’s TriNav platform and PEDD technology beyond liver-focused indications into a broader range of tumor types.
Szela also noted that the company has seen growing engagement from physicians and increased utilization of the PEDD platform, reflecting rising interest in its potential clinical benefits. With Dr. Marshall stepping into the CMO role, TriSalus aims to accelerate the generation of both clinical and economic data that demonstrate the value of its technology. This includes not only improving patient outcomes but also supporting healthcare systems in delivering more efficient and cost-effective care.
Dr. Marshall brings extensive clinical and academic experience to his new role. He is a board-certified interventional radiologist with a background that spans interventional oncology, hepatobiliary interventions, and trauma care. His training began at Tulane University School of Medicine, where he earned his medical degree. He then completed a diagnostic radiology residency at the Ochsner Clinic Foundation, serving as Chief Resident during his tenure. Following this, he pursued advanced fellowship training in interventional radiology and interventional oncology at Weill Cornell University and Memorial Sloan Kettering Cancer Center, two leading institutions in the field of cancer care and research.
After completing his training, Dr. Marshall joined the faculty at the Louisiana State University Health Sciences Center, where he made significant contributions to both clinical practice and medical education. Notably, he established Louisiana’s first Interventional Radiology Residency program, helping to train the next generation of specialists in this highly technical field. He also led a high-volume clinical practice focused on interventional oncology, hepatobiliary procedures, and trauma-related interventions.
In addition to his work at LSU, Dr. Marshall has been affiliated with Tulane University since 2021, where he has remained actively involved in teaching medical students and residents. His clinical experience is broad and includes treating patients undergoing organ transplantation, performing pediatric interventional procedures, conducting embolization treatments for conditions such as thyroid disease and uterine fibroids, managing musculoskeletal pain, and delivering venous and palliative care interventions. This diverse background provides him with a comprehensive understanding of patient needs across a wide range of clinical scenarios.
Upon accepting the new role, Dr. Marshall expressed enthusiasm about the opportunity to further contribute to TriSalus’ mission. He noted that the company is addressing critical challenges in the treatment of difficult-to-manage cancers, particularly liver and pancreatic tumors, where existing therapies often fall short. He also emphasized his commitment to advancing the company’s clinical and medical efforts, leveraging the potential of the PEDD platform to improve both the safety and effectiveness of cancer treatments.
Dr. Marshall highlighted the importance of continuing to build robust clinical evidence to support the adoption of innovative technologies like PEDD. By demonstrating improved drug delivery and better patient outcomes, TriSalus aims to establish its platform as a valuable tool in the oncology landscape. His leadership will be instrumental in guiding these efforts, ensuring that clinical development programs are aligned with both scientific objectives and patient needs.
The appointment of Dr. Marshall as Chief Medical Officer underscores TriSalus Life Sciences’ commitment to strengthening its leadership team as it advances its pipeline and technology platforms. As the company continues to expand the applications of its PEDD system and integrate it with emerging immunotherapies, having experienced clinical leadership in place is critical to navigating the complexities of oncology drug development and commercialization.
Overall, this leadership transition reflects TriSalus’ strategic focus on innovation, clinical excellence, and patient-centered care. With Dr. Marshall at the helm of its medical organization, the company is well-positioned to accelerate the development of its technologies and deliver meaningful advancements in the treatment of solid tumors.
About TriSalus Life Sciences
TriSalus Life Sciences ® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy.
The Company’s three FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav ® Infusion System and TriNav Infusion System LV for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes.
Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically.
The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development.
Source Link:https://www.businesswire.com/
